Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
The Atez/Bev and Dur/Tre regimens afforded comparable survival outcomes but differed substantially in safety and effects on the hepatic functional reserve. Given the trade-off between immunotoxicity and liver function preservation, treatment selection for CP-B liver function should be individualized, considering baseline hepatic reserve, tolerability, and anticipated treatment trajectory.
Authors
- Kazunari Tanaka (ORCID: https://orcid.org/0000-0001-9811-2665)
- Yuki Kanayama (ORCID: https://orcid.org/0000-0002-8639-5212)
- Tomomitsu Matono
- Hidenao Noritake (ORCID: https://orcid.org/0000-0003-3649-5335)
- Kazuhito Kawata (ORCID: https://orcid.org/0000-0002-4986-8578)
- Hideyuki Tamai (ORCID: https://orcid.org/0000-0003-4511-4573)
- Takeshi Hatanaka (ORCID: https://orcid.org/0000-0003-3656-285X)
- Kunihiko Tsuji (ORCID: https://orcid.org/0009-0007-4152-9364)
- Takashi Aoki (ORCID: https://orcid.org/0000-0003-0357-3245)
- Takuya Nagano (ORCID: https://orcid.org/0000-0003-1043-8033)
- Ei Itobayashi (ORCID: https://orcid.org/0000-0003-0475-2819)
- S KIM
- TOSHIFUMI TADA
- Masashi Hirooka (ORCID: https://orcid.org/0000-0001-5634-5313)
- Hiroko Iijima (ORCID: https://orcid.org/0000-0002-5841-8827)
- Hisashi Kosaka (ORCID: https://orcid.org/0000-0002-2926-9973)
- Kazuto Tajiri (ORCID: https://orcid.org/0000-0002-2373-8601)
- Akemi Tsutsui (ORCID: https://orcid.org/0000-0003-2978-2723)
- Satoru Kakizaki (ORCID: https://orcid.org/0000-0002-1508-584X)
- Satoaki Nakamura (ORCID: https://orcid.org/0000-0001-5721-3734)
- Yuichi Koshiyama (ORCID: https://orcid.org/0009-0006-1247-1215)
- Fujimasa Tada (ORCID: https://orcid.org/0009-0007-3964-5876)
- T. Fukumoto
- Michitaka Imai (ORCID: https://orcid.org/0000-0001-6448-6036)
- Kosuke Matsui (ORCID: https://orcid.org/0000-0002-7274-0177)
- Osamu Yoshida
- Kazuhiro Nouso
- Masaki Kaibori
- Hideko Ohama
- Chikara Ogawa
- A. Hiraoka
- Y. Hiasa
- Joji Tani
- Jumpei Okamura
- Asahiro Morishita
- Kazuya Kariyama
- Takashi Kumada
- Masanori Atsukawa
- Toru Ishikawa
- Taeang Arai
- Hiroki Nishikawa
- Yoshihide Ueda
- Yoshiko Nakamura
- Hidekatsu Kuroda
- Shohei Komatsu
- Hironori Tanaka
- Koichi Takaguchi
- Hidenori Toyoda
- Yutaka Yata
- Hironori Ochi
- Takashi Nishimura
- Atsushi Naganuma
- Takanori Matsuura
- the RELPEC Group and HCC 48 Group
- Tomomi Okubo
- Masatoshi Kudo
Institutions
- Hiroshima University (JP)
- Kansai Medical University (JP)
- Iwate Medical University (JP)
- Kagawa University (JP)
- Hamamatsu University School of Medicine (JP)
- Wakayama Rosai Hospital (JP)
- Niigata Cancer Center Hospital (JP)
- Takamatsu Red Cross Hospital (JP)
- Saiseikai Niigata Daini Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Matsuyama Red Cross Hospital (JP)
- Ogaki Municipal Hospital (JP)
- Himeji Medical Center (JP)
- Hanwa Memorial Hospital (JP)
- Gunma Saiseikai Maebashi Hospital (JP)
- Himeji Red Cross Hospital (JP)
- Kagawa University Hospital (JP)
- Teine Keijinkai Hospital (JP)
- Asahi General Hospital (JP)
- Toyama University Hospital (JP)
- Ehime Prefectural Central Hospital (JP)
- Kobe Asahi Hospital (JP)
- Kagawa Prefectural Central Hospital (JP)
- Takarazuka City Hospital (JP)
- Ehime University (JP)
- Gifu Kyoritsu University (JP)
- Kobe University (JP)
- Nippon Medical School (JP)
- Hyogo University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2026-01-09
- DOI
- https://doi.org/10.1111/hepr.70115
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 23.38